Results 241 to 250 of about 3,408 (305)

The role of venture‐financed startups in innovation for US agriculture

open access: yesAmerican Journal of Agricultural Economics, EarlyView.
Abstract To evaluate the role played by startup companies in the innovation ecosystem of US agriculture, we compile a unique dataset of 6024 new entrants founded 1987–2019 that details their financing lifecycles, annual economic performance, and patenting activities.
Gregory D. Graff   +2 more
wiley   +1 more source

Intellectual Honesty

open access: yesJournal of Investigative Surgery, 2002
openaire   +2 more sources

The rain feels different under the same umbrella: Experiences with poverty across LGBTQ subgroups

open access: yesAmerican Journal of Community Psychology, EarlyView.
Abstract Population‐based survey data have demonstrated that LGBTQ communities report varying rates of economic insecurity, yet very little research directly assesses how pathways into and experiences with poverty look different among subgroups at the intersections of sexual orientation and gender identity (SOGI).
Bianca D. M. Wilson, Lillian Nguyen
wiley   +1 more source

Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real‐world study to comprehensively report muco‐cutaneous toxicities, infections, and efficacy of talquetamab in 151 patients across five countries with the longest follow‐up reported enabling better efficacy and ...
Murali Janakiram   +94 more
wiley   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez   +17 more
wiley   +1 more source

Contemplating on human dignity: who counts as human? [PDF]

open access: yesJ Med Ethics Hist Med
Jafari SA   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy